Davies, M. (2014). New modalities of cancer treatment for NSCLC: Focus on immunotherapy. Cancer Management and Research, 6, 63–75.
DOI Link
Purpose & Patient Population
PURPOSE: To review immunotherapeutic agents and strategies for the management of patients on immunotherapy
TYPES OF PATIENTS ADDRESSED: Patients receiving immunotherapy for non-small cell lung cancer
Type of Resource/Evidence-Based Process
RESOURCE TYPE: Expert opinion
Phase of Care and Clinical Applications
PHASE OF CARE: Active antitumor treatment
Guidelines & Recommendations
Provides overall guidelines for patients receiving immunotherapy:
- Antidiarrheals for grade 1 diarrhea, and corticosteroids if diarrhea progresses to grade 2
- Systemic corticosteroids for severe, persistent, or recurring adverse events
- Dose delay for moderate adverse events until recovery and discontinuation of treatment for severe reactions
Limitations
- Expert opinion level evidence
- Provides an overall general approach to the management of adverse events rather than specific treatment algorithms
Nursing Implications
Provides general concepts for the management of immune-related adverse events